Final CDA-AMC Recommendation Brings Canadians with Early-Stage Alzheimer's Disease One Step Closer to Accessing LEQEMBI® (lecanemab)
4 Articles
4 Articles
Final CDA-AMC Recommendation Brings Canadians with Early-Stage Alzheimer's Disease One Step Closer to Accessing LEQEMBI® (lecanemab)
Recommendation advances equitable access discussions for eligible Canadians and highlights the urgency of timely reimbursement, as Alzheimer’s disease progression does not wait MISSISSAUGA, ON and TORONTO, Aug. 27, 2026 /CNW/ — Eisai Limited (“Eisai”) and Biogen Canada Inc. are pleased to receive Canada’s Drug Agency (CDA-AMC)’s final positive recommendation supporting public reimbursement for LEQEMBI® (lecanemab), for …
Bioarctic's partner Eisai has announced that the Canadian Food Safety Authority has issued a final recommendation supporting public funding of Leqembi (lecanemab) for eligible patients in Canada with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Bioarctic's partner Eisai has announced that the Canadian Food Safety Authority has issued a final recommendation supporting public funding of Leqembi (lecanemab) for eligible patients in Canada with mild cognitive impairment or mild dementia due to Alzheimer's disease.
This recommendation advances discussions on equitable access for Canadians... The post The CMA's final recommendation brings a step closer to access to LEQEMBI (lecanemab) for Canadians with Alzheimer's disease at an early stage appeared first on Les Affaires.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
